Navigation Links
Codexis Expands Codex® Panel Product Family at CPhI
Date:10/4/2010

REDWOOD CITY, Calif., Oct. 4 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced the expansion of its line of Codex® Panels with the introduction of Codex® Screening Kits. The Codex® Screening Kits are developed from, and complement, the established Codex® Panels biocatalyst screening plates.  Codex® Panels are used by more than 15 pharmaceutical and fine chemical companies worldwide, including Roche and Merck, to reduce pharmaceutical manufacturing process development time and costs.

They are being introduced this week at CPhI Worldwide, a global pharmaceutical ingredients convention in Paris (www.cphi.com).  

Codexis custom biocatalysts have reduced process chemistry development times from months to weeks, increased manufacturing efficiency and lowered manufacturing costs for both development stage and commercial drugs.  Codex® Panels have provided pharmaceutical process chemists access to a broad selection of Codexis custom enzymes which have been successfully used to develop processes for challenging manufacturing steps.  

The new Codex® Screening Kits contain a selection of 24 of the top-performing enzymes from Codexis' extensive collection of biocatalyst variants.  The Codex® Screening Kits are presented in a standard vial format to enhance ease of use for the process chemist, and were selected to deliver broad screening potential but with fewer enzymes than the Codex® Panels.  The Codex® Panels were first introduced in 2007, and are now available representing five common enzyme classes.  Codex® Screening Kits representing the two most commonly used enzyme classes, ketoreductase and transaminase enzymes, will be introduced this week.  For more product information, see www.codexis.com/products.

"Codex® Panels were introduced nearly four years ago with Merck as our first customer.  They have been widely adopted by pharmaceutical companies to improve manufacturing process development productivity," said Joseph Sarret, M.D., President, Codexis Pharmaceuticals Services & Enzyme Products.  "The Codex® Screening Kits will enable our customers to incorporate this powerful technology more broadly throughout their development pipelines."

Codexis is a clean technology company.  Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient.  Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell.  Other potential markets include carbon capture, water treatment and chemicals.  For more information, see www.codexis.com.

This press release contains forward-looking statements relating to Codexis' Codex® Panels biocatalyst screening plates and the Codex®  Screening Kits .  You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Factors that could materially affect actual results can be found in Codexis' Quarterly Report on Form 10-Q dated August 6, 2010 including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.Contacts:  Investors:  Derick Sutton, derick.sutton@codexis.com, 650-421-8130Media: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-377
'/>"/>

SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis to Present at the Pacific Crest Technology Leadership Forum
2. Codexis Names Peter Strumph SVP, Commercial Operations
3. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
4. Codexis, Inc. Announces Pricing of Initial Public Offering
5. Codexis Expands Pharmaceutical Manufacturing Partnerships
6. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Codexis Expands Collaboration with Teva
8. Codexis Names Fernando Valle Research Fellow
9. Pharmatek Laboratories Expands GMP Manufacturing Capabilities
10. CareFusion Expands Skin Antisepsis Portfolio
11. China BCT Further Expands its Footprint by Acquiring 33 Retail Pharmaceutical Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Research and Markets has announced the addition of ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:2/21/2017)... DUBLIN , Feb. 21, 2017 Research and ... and Strategies - 2016" report to their offering. ... The latest research Anthrax Drugs Price Analysis ... global Anthrax market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Anthrax market? ...
(Date:2/20/2017)... , Feb. 20, 2017 Provides understanding ... and agreements entered into by the worlds leading ... https://www.reportbuyer.com/product/3605699/ Description The Global Renal Failure ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been ... to surgery, treatment, therapy and management. Regular exercise in proper environments has been ... despite their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... coverage in veterinary medicine, will be launching its first bi-monthly issue of 2017 ... medicine, business and practice management, and One Health. , In making the ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to ... backed by giants including Accenture, GE Ventures, and Software AG , will ...
(Date:2/21/2017)... , ... February 21, 2017 , ... A February 6 ... gastric balloons for weight loss. It found that the treatments have led to significant ... patients, when compared to unassisted efforts. It also noted very few problematic results relating ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):